VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy

References

• Aiello LP, Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl. 2000;77:S113–S9.
   PubMed Web of Science ®Google Scholar
• Antonetti DA, Klein R, Gardner TW. Diabetic retinopathy. N Engl J Med. 2012;366(13):1227–1239.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Houck K, Jakeman L, et al. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992;13(1):18–32.
   PubMed Web of Science ®Google Scholar
• Vitt UA, Hsu SY, Hsueh AJW. Evolution and classification of cystine knot-containing hormones and related extracellular signaling molecules. Mol Endocrinol. 2001;15(5):681–694.
   PubMedGoogle Scholar
• Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380(6573):439–442.
   PubMed Web of Science ®Google Scholar
• Breier G. Functions of the VEGF/VEGF receptor system in the vascular system. Semin Thromb Hemost. 2000;26(5):553–559.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci. 2005;109(3):227–241.
   PubMed Web of Science ®Google Scholar
• Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001;114(Pt 5):853–865.
   PubMed Web of Science ®Google Scholar
• Olofsson B, Pajusola K, von Euler G, et al. Genomic organization of the mouse and human genes for vascular endothelial growth factor B (VEGF-B) and characterization of a second splice isoform. J Biol Chem. 1996;271(32):19310–19317.
   PubMed Web of Science ®Google Scholar
• Wang ZG, Puri TS, Quigg RJ. Characterization of novel VEGF (vascular endothelial growth factor)-C splicing isoforms from mouse. Biochem J. 2010;428(3):347–354.
   PubMed Web of Science ®Google Scholar
• Baldwin ME, Roufail S, Halford MM, et al. Multiple forms of mouse vascular endothelial growth factor-D are generated by RNA splicing and proteolysis. J Biol Chem. 2001;276(47):44307–44314.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581–611.
   PubMed Web of Science ®Google Scholar
• Ogawa S, Oku A, Sawano A, et al. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem. 1998;273(47):31273–31282.
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Matsunaga Y, Tokunaga Y, et al. Snake venom vascular endothelial growth factors (VEGF-Fs) exclusively vary their structures and functions among species. J Biol Chem. 2009;284(15):9885–9891.
   PubMed Web of Science ®Google Scholar
• Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407(6801):242–248.
   PubMed Web of Science ®Google Scholar
• Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev. 2002;82(3):673–700.
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146(5):1029–1039.
   PubMed Web of Science ®Google Scholar
• Sondell M, Sundler F, Kanje M. Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor. Eur J Neurosci. 2000;12(12):4243–4254.
   PubMed Web of Science ®Google Scholar
• Storkebaum E, Lambrechts D, Carmeliet P. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays. 2004;26(9):943–954.
   PubMed Web of Science ®Google Scholar
• Li X, Lee C, Tang Z, et al. VEGF-B: a survival, or an angiogenic factor? Cell Adh Migr. 2009;3(4):322–327.
   PubMed Web of Science ®Google Scholar
• Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science. 1997;276(5317):1423–1425.
   PubMed Web of Science ®Google Scholar
• Cao Y, Linden P, Farnebo J, et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci USA. 1998;95(24):14389–14394.
   PubMed Web of Science ®Google Scholar
• Marconcini L, Marchio S, Morbidelli L, et al. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc Natl Acad Sci U S A. 1999;96(17):9671–9676.
   PubMed Web of Science ®Google Scholar
• Stacker SA, Caesar C, Baldwin ME, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med. 2001;7(2):186–191.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Aiello LP, Rosenfeld PJ. Anti-vascular endothelial growth factor agents in the treatment of retinal disease: from bench to bedside. Ophthalmology. 2016;123(10S):S78–S88.
   PubMed Web of Science ®Google Scholar
• Cabral T, Mello LGM, Lima LH, et al. Retinal and choroidal angiogenesis: a review of new targets. Int J Retina Vitreous. 2017;3:31.
   PubMedGoogle Scholar
• Penn JS, Madan A, Caldwell RB, et al. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27(4):331–371.
   PubMed Web of Science ®Google Scholar
• Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995;270(3):1230–1237.
   PubMed Web of Science ®Google Scholar
• Grant MB, Mames RN, Fitzgerald C, et al. Insulin-like growth factor I as an angiogenic agent. In vivo and in vitro studies. Ann NY Acad Sci. 1993;692:230–242.
   PubMed Web of Science ®Google Scholar
• Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev. 1997;13(1):37–50.
   PubMed Web of Science ®Google Scholar
• Stone J, Itin A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci. 1995;15(7 Pt 1):4738–4747.
   PubMed Web of Science ®Google Scholar
• Reichenbach A, Bringmann A. Glia of the human retina. Glia. 2020;68(4):768–796.
   PubMed Web of Science ®Google Scholar
• Ida H, Tobe T, Nambu H, et al. RPE cells modulate subretinal neovascularization, but do not cause regression in mice with sustained expression of VEGF. Invest Ophthalmol Vis Sci. 2003;44(12):5430–5437.
   PubMed Web of Science ®Google Scholar
• Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets. 2005;6(4):511–524.
   PubMed Web of Science ®Google Scholar
• Shankar A, Mitchell P, Rochtchina E, et al. Association between circulating white blood cell count and long-term incidence of age-related macular degeneration: the blue mountains eye study. Am J Epidemiol. 2006;165(4):375–382.
   PubMed Web of Science ®Google Scholar
• Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353(8):782–792.
   PubMed Web of Science ®Google Scholar
• Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev. 2004;15(4):215–228.
   PubMed Web of Science ®Google Scholar
• Puddu A, Sanguineti R, Durante A, et al. Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: possible implication in ocular neovascularization. Mol Vis. 2012;18:2509–2517.
   PubMed Web of Science ®Google Scholar
• Zhao B, Ma A, Cai J, et al. VEGF-A regulates the expression of VEGF-C in human retinal pigment epithelial cells. Br J Ophthalmol. 2006;90(8):1052–1059.
   PubMed Web of Science ®Google Scholar
• Zhang SX, Wang JJ, Gao G, et al. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol. 2006;37(1):1–12.
   PubMed Web of Science ®Google Scholar
• Kociok N, Joussen AM. Varied expression of functionally important genes of RPE and choroid in the macula and in the periphery of normal human eyes. Graefes Arch Clin Exp Ophthalmol. 2007;245(1):101–113.
   PubMed Web of Science ®Google Scholar
• Leasher JL, Bourne RR, Flaxman SR, on behalf of the Vision Loss Expert Group of the Global Burden of Disease Study, et al. Vision loss expert group of the global burden of disease study. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. Diabetes Care. 2016;39(9):1643–1649.
   PubMed Web of Science ®Google Scholar
• Havens SJ, Gulati V. Neovascular glaucoma. Dev Ophthalmol. 2016;55:196–204.
   PubMedGoogle Scholar
• Stitt AW, Curtis TM, Chen M, et al. The progress in understanding and treatment of diabetic retinopathy. Prog Retin Eye Res. 2016;51:156–186.
   PubMed Web of Science ®Google Scholar
• Antonetti DA, Barber AJ, Hollinger LA, et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem. 1999;274(33):23463–23467.
   PubMed Web of Science ®Google Scholar
• Behzadian MA, Windsor LJ, Ghaly N, et al. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. Faseb J. 2003;17(6):752–754.
   PubMed Web of Science ®Google Scholar
• Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol. 2006;8(11):1223–1234.
   PubMed Web of Science ®Google Scholar
• Feng Y, Venema VJ, Venema RC, et al. VEGF-induced permeability increase is mediated by caveolae. Invest Ophthalmol Vis Sci. 1999;40(1):157–167.
   PubMed Web of Science ®Google Scholar
• Hofman P, Blaauwgeers HG, Tolentino MJ, et al. VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Vascular endothelial growth factor-A. Curr Eye Res. 2000;21(2):637–645.
   PubMed Web of Science ®Google Scholar
• Daruich A, Matet A, Moulin A, et al. Mechanisms of macular edema: beyond the surface. Prog Retin Eye Res. 2018;63:20–68.
   PubMed Web of Science ®Google Scholar
• Mesquita J, Castro-de-Sousa JP, Vaz-Pereira S, et al. Vascular endothelial growth factors and placenta growth factor in retinal vasculopathies: current research and future perspectives. Cytokine Growth Factor Rev. 2018;39:102–115.
   PubMed Web of Science ®Google Scholar
• Singh RP, Elman MJ, Singh SK, et al. Advances in the treatment of diabetic retinopathy. J Diabetes Complications. 2019;33(12):107417.
   PubMed Web of Science ®Google Scholar
• Witmer AN, Vrensen GF, Van Noorden CJ, et al. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22(1):1–29.
   PubMed Web of Science ®Google Scholar
• Shibuya M. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol. 2006;39(5):469–478.
   PubMedGoogle Scholar
• Takagi H, Koyama S, Seike H, et al. Potential role of the angiopoietin/tie2 system in ischemia-induced retinal neovascularization. Invest Ophthalmol Vis Sci. 2003;44(1):393–402.
   PubMed Web of Science ®Google Scholar
• Oh H, Takagi H, Otani A, et al. Selective induction of neuropilin-1 by vascular endothelial growth factor (VEGF): a mechanism contributing to VEGF-induced angiogenesis. Proc Natl Acad Sci USA. 2002;99(1):383–388.
   PubMed Web of Science ®Google Scholar
• Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID study group. EURODIAB controlled trial of lisinopril in Insulin-Dependent diabetes mellitus. Lancet. 1998;351(9095):28–31.
   PubMed Web of Science ®Google Scholar
• Rennel E, Guan WE, Schüler H, et al. S. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br J Cancer. 2008;98(7):1250–1257.
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349(5):427–434.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36(4):331–335.
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740–745.
   PubMed Web of Science ®Google Scholar
• Spasic M, Chow F, Tu C, et al. Molecular characteristics and pathways of avastin for the treatment of glioblastoma multiforme. Neurosurg Clin N Am. 2012;23(3):417–427.
   PubMed Web of Science ®Google Scholar
• Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006;26(9):999–1005.
   PubMed Web of Science ®Google Scholar
• Stefanini FR, Arevalo JF, Maia M. Bevacizumab for the management of diabetic macular edema. World J Diabetes. 2013;4(2):19–26.
   PubMedGoogle Scholar
• Choovuthayakorn J, Tantraworasin A, Phinyo P, et al. Factors associated with 1-year visual response following intravitreal bevacizumab treatment for diabetic macular edema: a retrospective single center study. Int J Retina Vitreous. 2021;7(1):17.
   PubMedGoogle Scholar
• Scott IU, Edwards AR, Beck RW, Diabetic Retinopathy Clinical Research Network, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114(10):1860–1867.
   PubMed Web of Science ®Google Scholar
• Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117(6):1078–1086.e2.
   PubMed Web of Science ®Google Scholar
• Rajendram R, Fraser-Bell S, Kaines A, et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130(8):972–979.
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. A. Guidelines for the management of diabetic macular edema by the european society of retina specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222.
   PubMed Web of Science ®Google Scholar
• Lee JH, Canny MD, De Erkenez A, et al. A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci USA. 2005;102(52):18902–18907.
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET, Jr, et al. VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805–2816.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26(8):859–870.
   PubMed Web of Science ®Google Scholar
• Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res. 2007;85(4):425–430.
   PubMed Web of Science ®Google Scholar
• Vaidyanathan U, Moshirfar M. Ranibizumab. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.
   Google Scholar
• Platania CB, Di Paola L, Leggio GM, et al. Molecular features of interaction between VEGFA and anti-angiogenic drugs used in retinal diseases: a computational approach. Front Pharmacol. 2015;6:248.
   PubMed Web of Science ®Google Scholar
• Yang J, Wang X, Fuh G, et al. Comparison of binding characteristics and in vitro activities of three inhibitors of vascular endothelial growth factor A. Mol Pharm. 2014;11(10):3421–3430.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Shah SM, Khwaja AA, et al. READ-2 study group. Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117(11):2146–2151.
   PubMed Web of Science ®Google Scholar
• Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33(11):2399–2405.
   PubMed Web of Science ®Google Scholar
• Mitchell P, Bandello F, Schmidt-Erfurth U, et al. Weichselberger A; RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–625.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Brown DM, Marcus DM, RISE and RIDE Research Group, et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012;119(4):789–801.
   PubMed Web of Science ®Google Scholar
• Comyn O, Sivaprasad S, Peto T, et al. A randomized trial to assess functional and structural effects of ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). Am J Ophthalmol. 2014;157(5):960–970.
   PubMed Web of Science ®Google Scholar
• Ishibashi T, Li X, Koh A, REVEAL Study Group, et al. The REVEAL study: ranibizumab monotherapy or combined with laser versus laser monotherapy in Asian patients with diabetic macular edema. Ophthalmology. 2015;122(7):1402–1415.
   PubMed Web of Science ®Google Scholar
• Pearce I, Banerjee S, Burton BJ, RELIGHT Study Group, et al. Ranibizumab 0.5 mg for diabetic macular edema with bimonthly monitoring after a phase of initial treatment: 18-Month, multicenter, phase IIIB RELIGHT study. Ophthalmology. 2015;122(9):1811–1819.
   PubMed Web of Science ®Google Scholar
• Prünte C, Fajnkuchen F, Mahmood S, RETAIN Study Group, et al. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol. 2016;100(6):787–795.
   PubMed Web of Science ®Google Scholar
• Sepah YJ, Sadiq MA, Boyer D, READ-3 Study Group, et al. Twenty-four-Month outcomes of the ranibizumab for edema of the macula in Diabetes – Protocol 3 with high dose (READ-3) study. Ophthalmology. 2016;123(12):2581–2587.
   PubMed Web of Science ®Google Scholar
• Gross JG, Glassman AR, Jampol LM, Writing Committee for the Diabetic Retinopathy Clinical Research Network, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20):2137–2146.
   PubMed Web of Science ®Google Scholar
• Gross JG, Glassman AR, Liu D, Diabetic Retinopathy Clinical Research Network, et al. Diabetic retinopathy clinical research network. Five-year outcomes of panretinal photocoagulation vs. intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2018;136(10):1138–1148.
   PubMed Web of Science ®Google Scholar
• Wells JA, Glassman AR, Ayala AR, Diabetic Retinopathy Clinical Research Network, et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203.
   PubMed Web of Science ®Google Scholar
• Singer MA, Miller DM, Gross JG, et al. Visual acuity outcomes in diabetic macular edema with fluocinolone acetonide 0.2 μg/day versus ranibizumab plus deferred laser (DRCR protocol I). Ophthalmic Surg Lasers Imaging Retina. 2018;49(9):698–706.
   PubMed Web of Science ®Google Scholar
• Payne JF, Wykoff CC, Clark WL, TREX-DME Study Group, et al. Randomized trial of treat and extend ranibizumab with and without navigated laser for diabetic macular edema: TREX-DME 1 year outcomes. Ophthalmology. 2017;124(1):74–81.
   PubMed Web of Science ®Google Scholar
• Payne JF, Wykoff CC, Clark WL, TREX-DME Study Group, et al. Randomized trial of treat and extend ranibizumab with and without navigated laser versus monthly dosing for diabetic macular edema: TREX-DME 2-Year outcomes. Am J Ophthalmol. 2019;202:91–99.
   PubMed Web of Science ®Google Scholar
• Payne JF, Wykoff CC, Clark WL, TREX-DME Study Group, et al. Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results. Br J Ophthalmol. 2021;105(2):253–257.
   PubMed Web of Science ®Google Scholar
• Fechter C, Frazier H, Marcus WB, et al. Ranibizumab 0.3 mg for persistent diabetic macular edema after recent, frequent, and chronic bevacizumab: the ROTATE trial. Ophthalmic Surg Lasers Imag Retina. 2016;47(11):1–18.
   PubMed Web of Science ®Google Scholar
• Lang GE, Liakopoulos S, Vögeler J, et al. The RELATION study: efficacy and safety of ranibizumab combined with laser photocoagulation treatment versus laser monotherapy in NPDR and PDR patients with diabetic macular oedema. Acta Ophthalmol. 2018;96(3):e377–e385.
   PubMed Web of Science ®Google Scholar
• Li X, Dai H, Li X, REFINE study group, et al. Efficacy and safety of ranibizumab 0.5 mg in chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study. Graefes Arch Clin Exp Ophthalmol. 2019;257(3):529–541.
   PubMed Web of Science ®Google Scholar
• Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99(17):11393–11398.
   PubMed Web of Science ®Google Scholar
• Cheng YD, Yang H, Chen GQ, et al. Molecularly targeted drugs for metastatic colorectal cancer. Drug Des Devel Ther. 2013;7:1315–1322.
   PubMed Web of Science ®Google Scholar
• Mansour AM, Al-Ghadban SI, Yunis MH, et al. Ziv-aflibercept in macular disease. Br J Ophthalmol. 2015;99(8):1055–1059.
   PubMed Web of Science ®Google Scholar
• Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–2254.
   PubMed Web of Science ®Google Scholar
• Brown DM, Schmidt-Erfurth U, Do DV, et al. Intravitreal aflibercept for diabetic macular edema: 100-Week results from the VISTA and VIVID studies. Ophthalmology. 2015;122(10):2044–2052.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Le RT, Khurana RN, ENDURANCE Study Group, et al. Outcomes with as-needed aflibercept and macular laser following the phase III VISTA DME trial: ENDURANCE 12-month extension study. Am J Ophthalmol. 2017;173:56–63.
   PubMed Web of Science ®Google Scholar
• Baker CW, Glassman AR, Beaulieu WT, DRCR Retina Network, et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA. 2019;321(19):1880–1894.
   PubMed Web of Science ®Google Scholar
• Maturi RK, Glassman AR, Josic K, DRCR Retina Network, et al. Effect of intravitreous anti-Vascular endothelial growth factor vs sham treatment for prevention of Vision-Threatening complications of diabetic retinopathy: the protocol W randomized clinical trial. JAMA Ophthalmol. 2021;139(7):701–712.
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang J, Yan M, et al. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys. Mol Vis. 2008;14:37–49.
   PubMed Web of Science ®Google Scholar
• Suto K, Yamazaki Y, Morita T, et al. Crystal structures of novel vascular endothelial growth factors (VEGF) from snake venoms: insight into selective VEGF binding to kinase insert domain-containing receptor but not to fms-like tyrosine kinase-1. J Biol Chem. 2005;280(3):2126–2131.
   PubMed Web of Science ®Google Scholar
• Liu K, Wang H, He W, et al. Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. Br J Ophthalmol. 2021;:2020–318690.
   Web of Science ®Google Scholar
• Li F, Zhang L, Wang Y, et al. One-year outcome of conbercept therapy for diabetic macular edema. Curr Eye Res. 2018;43(2):218–223.
   PubMed Web of Science ®Google Scholar
• Cai S, Yang Q, Li X, et al. The efficacy and safety of aflibercept and conbercept in diabetic macular edema. Drug Des Devel Ther. 2018;12:3471–3483.
   PubMed Web of Science ®Google Scholar
• Xu Y, Rong A, Bi Y, et al. Intravitreal conbercept injection with and without grid laser photocoagulation in the treatment of diffuse diabetic macular edema in real-life clinical practice. J Ophthalmol. 2016;2016:1–7.
   Web of Science ®Google Scholar
• Wang H, Guo J, Tao S, et al. One-Year effectiveness study of intravitreously administered conbercept® monotherapy in diabetic macular degeneration: a systematic review and meta-analysis. Diabetes Ther. 2020;11(5):1103–1117.
   PubMed Web of Science ®Google Scholar
• Yannuzzi NA, Freund KB. Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration. Clin Ophthalmol. 2019;13:1323–1329.
   PubMed Web of Science ®Google Scholar
• Sharma A, Kumar N, Kuppermann BD, et al. Brolucizimab-leading an era of structural revolution for long-term VEGF suppression. Eye. 2020;34(4):611–613.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Das A, Do DV, et al. Brolucizumab: evolution through preclinical and clinical studies and the implications for the management of neovascular age-related macular degeneration. Ophthalmology. 2020;127(7):963–976.
   PubMed Web of Science ®Google Scholar
• Tadayoni R, Sararols L, Weissgerber G, et al. Brolucizumab: a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration. Ophthalmologica. 2021;244(2):93–101.
   PubMed Web of Science ®Google Scholar
• Garweg JG. A randomized, Double-Masked, multicenter, phase III study assessing the efficacy and safety of brolucizumab versus aflibercept in patients with visual impairment due to diabetic macular edema (KITE). Klin Monbl Augenheilkd. 2020;237(4):450–453.
   PubMed Web of Science ®Google Scholar
• Stumpp MT, Binz HK, Amstutz P. DARPins: a new generation of protein therapeutics. Drug Discov Today. 2008;13(15–16):695–701.
   PubMed Web of Science ®Google Scholar
• Souied EH, Devin F, Mauget-Faÿsse M, MP0112 Study Group, et al. Treatment of exudative age-related macular degeneration with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol. 2014;158(4):724–732.e2.
   PubMed Web of Science ®Google Scholar
• Rodrigues GA, Mason M, Christie LA, et al. Functional characterization of Abicipar-Pegol, an anti-VEGF DARPin therapeutic that potently inhibits angiogenesis and vascular permeability. Invest Ophthalmol Vis Sci. 2018;59(15):5836–5846.
   PubMed Web of Science ®Google Scholar
• Nicolò M, Ferro Desideri L, Vagge A, et al. Faricimab: an investigational agent targeting the tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021;30(3):193–200.
   PubMed Web of Science ®Google Scholar
• Sahni J, Patel SS, Dugel PU, et al. Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth Factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial. Ophthalmology. 2019;126(8):1155–1170.
   PubMed Web of Science ®Google Scholar
• Striglia E, Caccioppo A, Castellino N, et al. Emerging drugs for the treatment of diabetic retinopathy. Expert Opin Emerg Drugs. 2020;25(3):261–271.
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network* Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA Ophthalmol. 2013;131(3):283–293.
   PubMed Web of Science ®Google Scholar
• Sivaprasad S, Prevost AT, Vasconcelos JC, CLARITY Study Group, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet. 2017;389(10085):2193–2203.
   PubMed Web of Science ®Google Scholar
• Figueira J, Fletcher E, Massin P, EVICR.net Study Group., et al. Ranibizumab plus panretinal photocoagulation versus panretinal photocoagulation alone for high-risk proliferative diabetic retinopathy (PROTEUS study). Ophthalmology. 2018;25(5):691–700.
   Web of Science ®Google Scholar
• Korobelnik JF, Daien V, Faure C, et al. Real-world outcomes following 12 months of intravitreal aflibercept monotherapy in patients with diabetic macular edema in France: results from the APOLLON study. Graefes Arch Clin Exp Ophthalmol. 2020;258(3):521–528.
   PubMed Web of Science ®Google Scholar
• Brown DM, Wykoff CC, Boyer D, et al. Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: Results from the PANORAMA randomized clinical trial. JAMA Ophthalmol. 2021;:e212809.
   Web of Science ®Google Scholar
• Alagorie AR, Velaga S, Nittala MG, et al. Effect of aflibercept on diabetic retinopathy severity and visual function in the RECOVERY study for proliferative diabetic retinopathy. Ophthalmol Retina. 2021;5(5):409–419.
   PubMedGoogle Scholar
• Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, et al. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2014;2014(11):CD008721.
   PubMedGoogle Scholar
• Simunovic MP, Maberley DA. Anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy: a systematic review and meta-analysis. Retina. 2015;35(10):1931–1942.
   PubMed Web of Science ®Google Scholar
• Bressler SB, Beaulieu WT, Glassman AR, et al. Diabetic retinopathy clinical research network. Factors associated with worsening proliferative diabetic retinopathy in eyes treated with panretinal photocoagulation or ranibizumab. Ophthalmology. 2017;124(4):431–439.
   PubMed Web of Science ®Google Scholar
• Gao S, Lin Z, Shen X. Anti-Vascular endothelial growth factor therapy as an alternative or adjunct to pan-retinal photocoagulation in treating proliferative diabetic retinopathy: meta-analysis of randomized trials. Front Pharmacol. 2020;11:849.
   PubMed Web of Science ®Google Scholar
• Fallico M, Maugeri A, Lotery A, et al. Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a systematic review and network meta-analysis. Acta Ophthalmol. 2021;99(6):e795–e805.
   PubMed Web of Science ®Google Scholar
• Maguire MG, Liu D, Glassman AR, DRCR Retina Network, et al. Visual field changes over 5 years in patients treated with panretinal photocoagulation or ranibizumab for proliferative diabetic retinopathy. JAMA Ophthalmol. 2020;138(3):285–293.
   PubMed Web of Science ®Google Scholar
• Sun JK, Glassman AR, Beaulieu WT, et al. Diabetic retinopathy clinical research network. Rationale and application of the protocol S anti-vascular endothelial growth factor algorithm for proliferative diabetic retinopathy. Ophthalmology. 2019;126(1):87–95.
   PubMed Web of Science ®Google Scholar
• Tan Y, Fukutomi A, Sun MT, et al. Anti-VEGF crunch syndrome in proliferative diabetic retinopathy: a review. Surv Ophthalmol. 2021;66(6):926–932.
   PubMed Web of Science ®Google Scholar
• Boyer DS, Yoon YH, Belfort R, Jr, Ozurdex MEAD Study Group., et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121(10):1904–1914.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, et al. Kane FE; FAME study group. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology. 2011;118(4):626–635.e2.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Brown DM, Pearson A, FAME Study Group, et al. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–2132.
   PubMed Web of Science ®Google Scholar